The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Abstract
Purpose: To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of a patient's tumor with the PFS for the most recent regimen on which the patient had experienced progression (ie, patient as his own control). Patients and Methods: Patients with refractory metastatic cancer had tissue samples submitted for MP in two formats including formalin-fixed tissue for immunohistochemistry and fluorescent in situ hybridization assays and immediately frozen tissue for oligonucleotide microarray (MA) gene expression assays (all performed in a Clinical Laboratory Improvement Amendments [ CLIA ] –certified laboratory). The MP approach was deemed of clinical benefit for the individual patient who had a PFS ratio (PFS on MP-selected therapy/PFS on prior therapy) of ≥ 1.3. Results: In 86 patients who had MP attempted, there was a molecular target detected in 84 (98%). Sixty-six of the 84 patients were treated according to MP results. Eighteen (27%) of 66 patients had a PFS ratio of ≥ 1.3 (95% CI, 17% to 38%; one-sided, one-sample P = .007). Therefore, the null hypothesis (that ≤ 15% of this patient population would have a PFS ratio of ≥ 1.3) was rejected. Conclusion: It is possible to identify molecular targets in patients' tumors from nine different centers across the United States. In 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression. Issues to be considered in interpretation of this study include limited prior experience with patients as their own controls as a study end point and overall patient attrition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dressman, H. K., Berchuck, A., Chan, G., Zhai, J., Bild, A., Sayer, R., Cragun, J., Clarke, J., Whitaker, R. S., Li, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3743 · Cited by 282
RetractedInhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
Self-citationCobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7915 · Cited by 443
Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling
Iwao-Koizumi, K., Matoba, R., Ueno, N., Kim, S. J., Ando, A., Miyoshi, Y., Maeda, E., Noguchi, S., & Kato, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.078 · Cited by 309
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242
Del Rio, M., Molina, F., Bascoul-Mollevi, C., Copois, V., Bibeau, F., Chalbos, P., Bareil, C., Kramar, A., Salvetat, N., Fraslon, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4187 · Cited by 210
Van Cutsem, E., Kang, Y., Chung, H., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba4509 · Cited by 203
Hoff, D. D. V. (1998) · PubMed · Cited by 199
Kihara, C., Tsunoda, T., Tanaka, T., Yamana, H., Furukawa, Y., Ono, K., Kitahara, O., Zembutsu, H., Yanagawa, R., Hirata, K., et al. (2001) · PubMed · Cited by 198
Chang, J. C., Makris, A., Gutierrez, M. C., Hilsenbeck, S. G., Hackett, J. R., Jeong, J., Liu, M.-L., Baker, J. B., Clark-Langone, K. M., Baehner, F. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9590-z · Cited by 136
Sørlie, T., Perou, C. M., Fan, C., Geisler, S. B., Aas, T., Nobel, A. B., Anker, G. B., Akslen, L. A., Botstein, D., Børresen‐Dale, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0126 · Cited by 135
O’Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D. A., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B. M., & Bradley, C. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.3 · Cited by 95
Smith, S., Su, D., de la Longrais, I. A. R., Schwartz, P. E., Puopolo, M., Rutherford, T., Mor, G., Yu, H., & Katsaros, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8547 · Cited by 94
Cutsem, E. V., Kang, Y., Chung, H., Shen, L., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.lba4509 · Cited by 90
Alternate Endpoints for Screening Phase II Studies
Dhani, N. C., Tu, D., Sargent, D. J., Seymour, L., & Moore, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2034 · Cited by 87
Tumor mRNA Expression Profiles Predict Responses to Chemotherapy
Minna, J. D., Girard, L., & Xie, Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3968 · Cited by 44
André, F., Mazouni, C., Hortobágyi, G. N., & Pusztai, L. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.002 · Cited by 31
Kim, E. S., Herbst, R. S., Lee, J. J., Blumenschein, G. R., Tsao, A. S., Wistuba, I. I., Alden, C. M., Gupta, S. K., Stewart, D. J., & Hong, W. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8024 · Cited by 17
Cited by
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 707
Metadata
- Authors
- Von Hoff, D. D., Stephenson, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D. A., Fitch, T. R., Wasserman, E., Fernandez, C., Green, S., Sutherland, W., Bittner, M., Alarcon, A., Mallery, D., & Penny, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-11-20
- Volume
- 28
- Issue
- 33
- Pages
- 4877-4883
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133296598
- Cited by
- 647
- References
- 18
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.